<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070340</url>
  </required_header>
  <id_info>
    <org_study_id>17-045</org_study_id>
    <nct_id>NCT03070340</nct_id>
  </id_info>
  <brief_title>Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery</brief_title>
  <official_title>Comparison of Breast Magnetic Resonance Imaging (MRI) and Contrast Enhanced Mammography (CEDM) to Evaluate Residual Disease Extent After Neoadjuvant Therapy (NAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the diagnostic accuracy of breast magnetic resonance&#xD;
      imaging (MRI) and contrast enhanced digital mammography (CEDM) in assessing the residual&#xD;
      disease extent in patients who have completed neoadjuvant therapy (NAT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare diagnostic accuracy of breast MRI and CEDM</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the diagnostic accuracy of enhancement on MRI and CEDM in evaluating residual disease extent in women who have completed NAT prior to surgical excision</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast MRI and Contrast Enhanced Mammography (CEDM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Breast Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.</description>
    <arm_group_label>Breast MRI and Contrast Enhanced Mammography (CEDM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast Enhanced Mammography (CEDM)</intervention_name>
    <description>All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.</description>
    <arm_group_label>Breast MRI and Contrast Enhanced Mammography (CEDM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any woman who has completed or is nearing completion of neoadjuvant therapy for breast&#xD;
             cancer and is scheduled for a post-NAT breast MRI and mammogram&#xD;
&#xD;
          -  Surgery (mastectomy or BCT) planned within 60 days of the MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who have a contraindication to the intravenous use of iodinated contrast agent&#xD;
             (i.e., allergy to iodinated contrast or severely impaired renal function with a&#xD;
             creatinine level &gt; 1.3 or eGFR â‰¥45)&#xD;
&#xD;
          -  Known allergic reaction to gadolinium; patient may be eligible if the referring&#xD;
             physician determines that the MRI is medically necessary and if the patient is willing&#xD;
             to undergo pre-medication for contrast allergy&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Male patients&#xD;
&#xD;
          -  Presence of non MR compatible metallic objects or metallic objects that, in the&#xD;
             opinion of the radiologist, would make MRI a contraindication&#xD;
&#xD;
          -  Known or suspected renal impairment. Requirements for GFR prior to MRI as determined&#xD;
             by local site standard practice&#xD;
&#xD;
          -  Women who have already had their standard of care post-NAT mammogram and/or breast MRI&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Sung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent only)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Consent only)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mastectomy</keyword>
  <keyword>breast MRI</keyword>
  <keyword>contrast enhanced mammography</keyword>
  <keyword>CEDM</keyword>
  <keyword>17-045</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

